Clinical Trial Update: Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases. [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating the imaging agent 68Ga-FXX489 (NNS309) for PET/CT-based diagnosis of tumor and metastatic cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Tumor

Drugs mentioned

• 68Ga-FXX489 (NNS309) (NNS309)

Snippet

Sponsor: Yi Tian | Conditions: Tumor, Metastatic Cancer | Phase 1 | Status: RECRUITING